A Busy Week for Multiple Sclerosis News

It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.

Read more »

MediciNova to Buy Avigen for $37 Million

Pharmaceutical company MediciNova announced that it will buy Avigen (AVGN) for $1.24 per share, approximately $37 million.

Read more »